Combined Diffuse Astrocytoma and Pleomorphic Xanthoastrocytoma Grade III Sharing IDH1 R132H Mutation

被引:1
|
作者
Tourne, Morgan [1 ]
Tauziede-Espariat, Arnault [1 ]
Dezamis, Edouard [2 ]
Saffroy, Raphael [3 ]
Dhermain, Frederic [4 ]
Chretien, Fabrice [1 ]
Varlet, Pascale [1 ]
机构
[1] Descartes Univ, St Anne Hosp, Dept Neuropathol, Paris, France
[2] Descartes Univ, St Anne Hosp, Dept Neurosurg, Paris, France
[3] Hop Univ Paris Sud, Hop Paul Brousse, AP HP, Dept Biochem & Oncogenet, Villejuif, France
[4] Gustave Roussy Canc Campus, Dept Radiat Oncol, Villejuif, France
关键词
Anaplastic astrocytoma; BRAF V600E; Collision tumour; IDH1; mutation; Pleomorphic xanthoastrocytoma; COLLISION TUMOR; MENINGIOMA; DIFFERENTIATION; FEATURES; GLIOMAS; BRAIN;
D O I
10.1016/j.wneu.2018.05.156
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
BACKGROUND: Collision tumors are often difficult to distinguish from intratumoral heterogeneity in diffuse gliomas. CASE DESCRIPTION: We report the case of a 44-year-old woman admitted for intracranial hypertension. Magnetic resonance imaging revealed a right intra-axial frontal mass, composed of a hypervascular nodular portion contrasting with a large nonenhanced infiltrative and muliticystic portion. Histopathologic examination showed the occurrence of two morphologically different gliomas. The largest component corresponded to an anaplastic astrocytoma, IDH1-mutated. The second corresponded to a leptomeningeal nodule, reminiscent of a pleomorphic xanthoastrocytoma. Both tumoral components exhibited anaplastic features, World Health Organization grade III. Immunohistochemical and molecular studies showed that the 2 components were identical, IDH1 R132H mutated but without BRAF V600E mutation. Tumor progression was assessed 2 years after surgery, after radiotherapy and chemotherapy, showing supratentorial leptomeningeal dissemination. CONCLUSIONS: Collision tumors and combined neoplasms have been rarely described in the brain and only 4 similar articles report the synchronous occurrence of 2 primary gliomas. A review of the literature is proposed, focusing on criteria that could be used to discriminate them.
引用
收藏
页码:316 / 321
页数:6
相关论文
共 50 条
  • [21] Gaining Insight into the Catalytic Mechanism of the R132H IDH1 Mutant: A Synergistic DFT Cluster and Experimental Investigation
    Broome, Joshua A.
    Nguyen, Nguyen P.
    Baumung, Cassidy R. E.
    Chen, Vincent C.
    Bushnell, Eric A. C.
    BIOCHEMISTRY, 2024, 63 (20) : 2682 - 2691
  • [22] The prognostic IDH1 R132 mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma
    Bleeker, Fonnet E.
    Atai, Nadia A.
    Lamba, Simona
    Jonker, Ard
    Rijkeboer, Denise
    Bosch, Klazien S.
    Tigchelaar, Wikky
    Troost, Dirk
    Vandertop, W. Peter
    Bardelli, Alberto
    Van Noorden, Cornelis J. F.
    ACTA NEUROPATHOLOGICA, 2010, 119 (04) : 487 - 494
  • [23] Diffuse Leptomeningeal Neuroepithelial Tumor 9 Pediatric Cases With Chromosome 1p/19q Deletion Status and IDH1 (R132H) Immunohistochemistry
    Schniederjan, Matthew J.
    Alghamdi, Sarah
    Castellano-Sanchez, Amilcar
    Mazewski, Claire
    Brahma, Barunashish
    Brat, Daniel J.
    Brathwaite, Carole D.
    Janss, Anna J.
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2013, 37 (05) : 763 - 771
  • [24] Low expression of isocitrate dehydrogenase 1 (IDH1) R132H is associated with advanced pathological features in laryngeal squamous cell carcinoma
    Shayanfar, Nasrin
    Zare-Mirzaie, Ali
    Mohammadpour, Mahsa
    Jafari, Ensieh
    Mehrtash, Amirhosein
    Emtiazi, Nikoo
    Tajik, Fatemeh
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (08) : 4253 - 4267
  • [25] Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma
    Raghunathan, Aditya
    Olar, Adriana
    Vogel, Hannes
    Parker, John R.
    Coventry, Susan C.
    Debski, Robert
    Albarracin, Constance T.
    Aldape, Kenneth D.
    Cahill, Daniel P., III
    Powell, Suzanne Z.
    Fuller, Gregory N.
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2012, 16 (04) : 255 - 259
  • [26] Characterization of IDH1 p.R132H Mutant Clones Using Mutation-specific Antibody in Myeloid Neoplasms
    Kurt, Habibe
    Bueso-Ramos, Carlos E.
    Khoury, Joseph D.
    Routbort, Mark J.
    Kanagal-Shamanna, Rashmi
    Patel, Umang V.
    Jorgensen, Jeffrey L.
    Wang, Sa A.
    Ravandi, Farhad
    DiNardo, Courtney
    Luthra, Rajyalakshmi
    Medeiros, L. Jeffrey
    Patel, Keyur P.
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2018, 42 (05) : 569 - 577
  • [27] Diffuse astrocytoma with mosaic IDH1-R132H-mutant immuno-phenotype and low subclonal allele frequency
    Morgan, Katherine M.
    Danish, Shabbar
    Xiong, Zhenggang
    INTRACTABLE & RARE DISEASES RESEARCH, 2022, 11 (01) : 43 - 45
  • [28] IDH1 R132H Mutation Enhances Cell Migration by Activating AKT-mTOR Signaling Pathway, but Sensitizes Cells to 5-FU Treatment as NADPH and GSH Are Reduced
    Zhu, Huixia
    Zhang, Ye
    Chen, Jianfeng
    Qiu, Jiangdong
    Huang, Keting
    Wu, Mindan
    Xia, Chunlin
    PLOS ONE, 2017, 12 (01):
  • [29] The R132H mutation in IDH1 promotes the recruitment of NK cells through CX3CL1/CX3CR1 chemotaxis and is correlated with a better prognosis in gliomas
    Ren, Feifei
    Zhao, Qitai
    Huang, Lan
    Zheng, Yujia
    Li, Lifeng
    He, Qianyi
    Zhang, Chaoqi
    Li, Feng
    Maimela, Nomathamsanqa R.
    Sun, Zhi
    Jia, Qingquan
    Ping, Yu
    Zhang, Zhen
    Chen, Xinfeng
    Yue, Ying
    Liu, Shasha
    Cao, Ling
    Zhang, Yi
    IMMUNOLOGY AND CELL BIOLOGY, 2019, 97 (05) : 457 - 469
  • [30] Detection of isocitrate dehydrogenase 1 mutation R132H in myelodysplastic syndrome by mutation-specific antibody and direct sequencing
    Andrulis, Mindaugas
    Capper, David
    Luft, Thomas
    Hartmann, Christian
    Zentgraf, Hanswalter
    von Deimling, Andreas
    LEUKEMIA RESEARCH, 2010, 34 (08) : 1091 - 1093